Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI334 in advanced solid tumors
NCT05774873Phase 2Completed
- Sponsor
- Innovent Biologics
- Start
- Aug 2023
- Primary completion
- Mar 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of IBI-334 in solid tumor, sponsored by Innovent Biologics. Started Aug 2023; status: completed.
02
Drugs
IBI-334
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05774873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05774873.